Preeclampsia Diagnostics Market
Number of pages: 100 | Report Format: PDF | Published date: May 29, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023 to 2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 1.35 billion |
|
Revenue Forecast in 2031 |
US$ 1.88 billion |
|
CAGR |
3.75% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Test Type, Product & Services, End User, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global preeclampsia diagnostics market was valued at US$ 1.35 billion in 2022 and is expected to register a revenue CAGR of 3.75% to reach US$ 1.88 billion by 2031.
Preeclampsia Diagnostics Market Fundamentals
Preeclampsia is a serious pregnancy complication that can threaten the mother and her unborn child. It is marked by elevated blood pressure and damage to vital organs like the liver and kidneys. This condition typically develops after the 20th week of pregnancy, affecting around 5-8% of expectant women globally. Preeclampsia diagnostics are a wide range of tests healthcare professionals use to detect and track the progression of preeclampsia during pregnancy. These tools are designed to identify the conditions early, allowing for rapid intervention and effective management to prevent serious complications.
Over the past few years, progress in medical technology and research has resulted in the creation of multiple ground-breaking diagnostic methods for preeclampsia. These approaches involve identifying biomarkers, conducting imaging studies, and utilizing predictive models to evaluate risk factors for developing preeclampsia. Moreover, imaging techniques, such as Doppler ultrasound, have also been employed to assess blood flow in the placenta and uterine arteries. Abnormal blood flow patterns may indicate an increased risk of developing preeclampsia, enabling proactive management strategies.
Many companies in the preeclampsia diagnostics industry are working to enhance the accuracy, efficiency, and accessibility of diagnostic tools, biomarkers, and technologies. Most of this involves investing in research and development to identify and validate new biomarkers. Additionally, market players are attempting to create point-of-care diagnostic tests that can provide quick and convenient results at the bedside or in locations with limited resources. These tests are designed to enable early detection and timely management of preeclampsia.
Preeclampsia Diagnostics Market Dynamics
Increasing incidences of preeclampsia are the major factor in increasing the revenue share of the global preeclampsia diagnostics market. Pre-eclampsia occurs when the placenta doesn't develop correctly because of issues with the blood vessels that provide it. According to the National Center for Biotechnology Information in February 2023, preeclampsia is a pregnancy-related hypertension disorder contributing to 2% to 8% of pregnancy complications globally. It leads to maternal deaths ranging from 9% to 26% in low-income countries and 16% in high-income countries. Moreover, studies have shown that women with advanced maternal age and who are overweight are more prone to preeclampsia. According to the National Center for Biotechnology Information in 2020, women aged 40 and above have a notably higher incidence of obstetric pathology, with 4.6% experiencing preeclampsia compared to 1.5% in the control group. Similarly, for gestational hypertension, the rate is 3.1% compared to 1.1% in the control group.
Additionally, many non-profit organizations are making new initiatives to increase awareness about the conditions. In November 2021, The Preeclampsia Foundation planned a Doula-focused educational webinar. The Preeclampsia Foundation has been educating women on preeclampsia’s signs and symptoms during pregnancy and making them aware that they are “still at risk” for postpartum preeclampsia following their baby’s delivery. The organization aims to spread its message in partnership with doulas nationwide. Furthermore, in June 2020, the Foundation increased the accessibility of the Cuff Kit, a self-monitoring blood pressure device, and educational tools around signs and symptoms of postpartum risk.
Top players are increasingly launching new devices to address the efficacy and convenience of preeclampsia diagnosis. A recent development in the medical field is Thermo Fisher Scientific's novel immunoassays receiving clearance from the US Food and Drug Administration (FDA) in May 2023. These assays are specifically designed to aid in evaluating the risk associated with preeclampsia, a serious pregnancy complication. They can be used with other laboratory tests and clinical assessments to assess the risk of pregnant women hospitalized due to hypertensive disorders during pregnancy.
However, in certain settings with limited resources, accessing advanced diagnostic technologies and tests for preeclampsia may be difficult due to high costs and specialized infrastructure and expertise requirements. This can hinder timely and accurate diagnosis, as diagnostic tools and tests may not be widely adopted due to their prohibitive costs. Moreover, obtaining regulatory approvals and reimbursement for new diagnostic devices and tests can be a lengthy and rigorous process.
Preeclampsia Diagnostics Market Ecosystem
The global preeclampsia diagnostics market is analyzed from four perspectives: test type, product & services, end user, and region.
Preeclampsia Diagnostics Market by Test Type
Based on test type, the global preeclampsia diagnostics market is segmented into urine tests and blood tests.
The blood tests segment accounted for 54% of the global preeclampsia diagnostics market share in 2022. This is primarily due to the accuracy and reliability of blood tests in detecting preeclampsia. Additionally, the increasing adoption of non-invasive prenatal testing (NIPT) has further propelled the growth of the blood tests segment. NIPT allows for early detection of preeclampsia, which can help prevent complications and improve maternal and fetal outcomes. As a result, many healthcare providers are opting for blood tests as a routine screening tool for preeclampsia.
The urine tests segment is expected to grow at a revenue CAGR of 4.2% during the forecast period. This growth can be attributed to the growing demand for point-of-care testing and the development of advanced urine testing technologies. Furthermore, the rising awareness among people regarding the importance of early diagnosis and prevention is expected to boost the demand for urine tests in the coming years.
Preeclampsia Diagnostics Market Product & Services
Based on products & services, the global preeclampsia diagnostics market is segmented into instruments, services, and reagents & consumables.
The services segment is expected to dominate the global preeclampsia diagnostics market and will maintain this dominance in the forecast period. The increasing demand for accurate and reliable diagnostic testing for pre-eclampsia and the growing awareness of the condition and its potential complications. As such, companies operating in this market will likely focus on developing innovative and effective diagnostic solutions to meet the needs of healthcare providers and patients.
Preeclampsia Diagnostics Market by End User
Based on end user, the global preeclampsia diagnostics market is segmented into hospitals, diagnostics laboratories, and others.
Hospitals dominate the global preeclampsia diagnostics market. This is major because hospitals have well-established infrastructure and resources to perform diagnostic tests, including blood pressure monitoring, urine analysis, and blood tests. Moreover, hospitals have experienced healthcare professionals who can accurately diagnose and manage preeclampsia. Hospitals also have access to advanced medical equipment and technology, enabling them to provide timely and effective treatment to patients. As a result, patients prefer to visit hospitals for pre-eclampsia diagnosis and treatment, thereby driving the growth of the hospital segment in the global preeclampsia diagnostics market.
Preeclampsia Diagnostics Market by Region
Based on the region, the preeclampsia diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, & the Middle East & Africa.
North America accounted for 37% of the preeclampsia diagnostics market revenue share 2022. This can be attributed to the increasing prevalence of pre-eclampsia in the region and the growing awareness among healthcare providers and patients about the importance of early diagnosis and management of the condition. According to the March of Dimes organization, approximately 5 to 8 percent of pregnancies in the United States are affected by this condition, which often results in preterm birth. Additionally, the region's availability of advanced diagnostic tools and technologies contributes to the market’s growth. The United States is expected to be the largest market for preeclampsia diagnostics in North America, owing to the country's high incidence of the condition. However, Canada is also expected to witness significant growth in the coming years, driven by increasing investments in healthcare infrastructure and rising healthcare expenditure.
The Asia Pacific preeclampsia diagnostics market is projected to show a significant growth of 4.52% CAGR in the forecast years. This growth is primarily driven by the increasing prevalence of preeclampsia in the region and the rising awareness about early diagnosis and treatment of the condition. Additionally, advancements in healthcare infrastructure and the availability of advanced diagnostic technologies are expected to boost market growth further.
Molecular diagnostics Competitive Landscape
Several companies emphasize development tactics, such as new launches, product approvals, and other elements like patents and events. The market saw acquisition, partnership, and cooperation activities as inorganic development tactics. These initiatives have enabled the expansion of future economic business prospects and increased demand for calcitonin in the global preeclampsia diagnostics market.
Some of the prominent companies having the largest revenue share in the global preeclampsia diagnostics market are,
Strategic Developments
Preeclampsia is a serious pregnancy complication that can threaten the mother and her unborn child. It is marked by elevated blood pressure and damage to vital organs like the liver and kidneys.
The global preeclampsia diagnostics market will be valued at US$ 1.88 billion by 2031.
The global preeclampsia diagnostics market has witnessed significant growth in recent years due to increasing research and development, increasing funding to nonprofit organizations, and increasing preference for early disease diagnosis.
The global preeclampsia diagnostics market is expected to register a revenue CAGR of 3.75% in the forecast period from 2013 to 2031.
North America region dominated the global preeclampsia diagnostics market with 37% of the market revenue share in 2022.
*Insights on financial performance are subject to the availability of information in the public domain